[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intellectual-disability-mild-to-moderate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intellectual-disability-mild-to-moderate":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100631779","comparing-the-impact-of-peer-support-vs-staff-delivered-transportation-interventions-for-young-adults-with-intellectual-and-developmental-disabilities-100631779",false,"NCT07505121","Comparing the Impact of Peer Support vs. Staff-Delivered Transportation Interventions for Young Adults With Intellectual and Developmental Disabilities.","Comparing Peer Support and Staff-Delivered Transportation Interventions for Young Adults With Intellectual and Developmental Disabilities (YA-IDD) on Loneliness, Social Participation, and Transportation Skills","YA-IDD","Inclusion Criteria:\n\n* Between the ages of 18 to 27 years old during the start of the study\n* Receives services at one of the eight community service organizations participating in the study.\n* Meets the federal diagnosis of a developmental disability (DD)\n* Qualifies for services related to their DD.\n* Scores \\>28 on the Transportation Prescreening Assessment (indicating readiness for travel).\n\nExclusion Criteria:\n\n* Independently uses public transportation \\>4 times\u002Fmonth.\n* Is not able to independently mobilize through walking or use of a mobility device.\n* Has significant non-corrected visual impairments.","ALL","18 Years","27 Years",{"count":21,"type":22},325,"ESTIMATED","INTERVENTIONAL",[25],"NA","This clinical trial will look at whether young adults with intellectual and developmental disabilities (YA-IDD) have better outcomes when a travel training intervention called Ready to Ride (R2R) is taught by a specially trained Peer Supporter (PS) who shares the lived experience of having an IDD than YA-IDD who are taught Ready to Ride by staff at their community services organization. The aspects of life being looked at are loneliness, satisfaction with social activities, travel skills, service use and access, employment, and health related quality of life.\n\nThe researchers think the following things will happen.\n\n1. YA-IDD who learn from a Peer Supporter will report significantly higher satisfaction with social activities, increased social connectedness and significantly less loneliness compared to YA who are taught organization staff.\n2. Both groups will learn the same amount of travel skills.\n3. YA-IDD who learn from a Peer Supporter will show larger increases in access to community-based services, transportation use, employment and health related services after 4 months than the YA taught by organizational staff.",[28,29],"Intellectual Disability, Mild to Moderate","Developmental Disability",[31,32,33,29,34,35],"Travel Training Intervention","Young Adults","Intellectual Disability","Transportation","Peer Support","NOT_YET_RECRUITING","2026-03-26",{"date":39,"type":40},"2026-04-01","ACTUAL",{"date":42,"type":22},"2026-05",{"date":44,"type":22},"2030-06",{"name":46,"class":47},"Temple University","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":5},"100600081","pgx-medication-safety-reviews-of-persons-with-idd-100600081","NCT07092852","PGx Medication Safety Reviews of Persons With IDD","Pharmacogenomic-Based Medication Safety Reviews of Persons With Intellectual and Developmental Disabilities","Inclusion Criteria:\n\n* Beneficiary with IDD\n* Reside in a CP Unlimited facility, NY state\n* At least 21 years of age\n\nExclusion Criteria:\n\n* Pregnant\n* Medical or physical abnormality that prevents cheek swab collection","21 Years",{"count":58,"type":22},700,"OBSERVATIONAL","The purpose of this study is to assess the feasibility of a comprehensive medication review and PGx initiative as part of the care process for individuals in the care of CP Unlimited. This initiative may help improve management of medications and overall health and well-being for participating individuals. Please note that in the context of the research being conducted, all information will remain confidential and deidentified for analyses.\n\nUnder the proposed study protocol, CP Unlimited, in partnership with pharmacists at GalenusRx, will implement and assess a comprehensive medication safety and PGx initiative. Almost three quarters of all clinical trials have eligibility criteria resulting in the exclusion of adults with IDD. This study will help address ongoing health practice disparity. As indicated above, the investigators are requesting the authorization of the guardian or representative, on behalf of the participant under their supervision, to enroll this individual in the proposed study because she\u002Fhe is currently prescribed medications or may eventually receive prescribed or over-the-counter medications. Hereinafter, the denomination \"he\u002Fshe, him\u002Fher, his\u002Fher or them\u002Ftheir\" will be used to refer to the individual with IDD.\n\nThe response to medication can be affected by variations in our genes and by other medications and various disease conditions. Information contained in our genes can vary from one patient to another patient and this can explain why we all can respond differently to medications. Genetic testing and a review of his\u002Fher medications can help to determine if the medication will work for him\u002Fher. PGx is how his\u002Fher genes affect the way he\u002Fshe responds to specific drugs. PGx can tell if he\u002Fshe is more or less likely to feel bad reactions to a drug, or if a drug is likely to benefit him\u002Fher and be safe for him\u002Fher to take. Knowing his\u002Fher genetic information and all medicines that he\u002Fshe is taking can help his\u002Fher pharmacist and his\u002Fher doctor find the combination of medicines that will work the best for him\u002Fher, now and in the future.",[62,28,29],"Intellectual Disability, Mild",[64,65,66,67],"Intellectual disabilities","Developmental disabilities","IDD","pharmacogenomics","2025-07-21",{"date":70,"type":40},"2025-07-30",{"date":72,"type":22},"2025-08-01",{"date":74,"type":22},"2028-01-31",{"name":76,"class":77},"GalenusRx, Inc.","INDUSTRY"]